A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects with Metastatic Prostate Cancer

Study identifier:4054IL/0004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

-

Medical condition

Prostatic Neoplasms

Phase

Phase 2

Healthy volunteers

No

Study drug

ZD4054 10 mg, ZD4054 15 mg, ZD4054 22.5 mg

Sex

Male

Actual Enrollment

22

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jun 2003
Primary Completion Date: 01 Oct 2005
Study Completion Date: 01 Oct 2005

Study design

Allocation: None
Endpoint Classification: None
Intervention Model: None
Masking: None
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2012 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria